Abstract:Human immunodeficiency virus (HIV) entry into cells is initiated by the binding of its envelope glycoprotein (Env) gp120 to receptor CD4. Antibodies that bind to epitopes overlapping the CD4-binding site (CD4bs) on gp120 can prevent HIV entry by competing with cell-associated CD4; their ability to outcompete CD4 is a major determinant of their neutralizing potency and is proportional to their avidity. The breadth of neutralization and the likelihood of the emergence of antibody-resistant virus are critically dependent on the structure of their epitopes. Because CD4bs is highly conserved, it is reasonable to hypothesize that antibodies closely mimicking CD4 could exhibit relatively broad cross-reactivity and a high probability of preventing the emergence of resistant viruses. Previously, in a search for antibodies that mimic CD4 or the co-receptor, we identified and characterized a broadly cross-reactive HIV-neutralizing CD4bs human monoclonal antibody (hmAb), m18. Here, we describe the crystal structure of Fab m18 at 2.03 A resolution, which reveals unique conformations of heavy chain complementarity-determining regions (CDRs) 2 and 3 (H2 and H3). H2 is highly bulged and lacks cross-linking interstrand hydrogen bonds observed in all four canonical structures. H3 is 17.5 A long and rigid, forming an extended beta-sheet decorated with an alpha-turn motif bearing a phenylalanine-isoleucine fork at the apex. It shows striking similarity to the Ig CDR2-like C'C'' region of the CD4 first domain D1 that dominates the binding of CD4 to gp120. Docking simulations suggest significant similarity between the m18 epitope and the CD4bs on gp120. Fab m18 does not enhance binding of CD4-induced (CD4i) antibodies, nor does it induce CD4-independent fusion mediated by the HIV Env. Thus, vaccine immunogens based on the m18 epitope structure are unlikely to elicit antibodies that could enhance infection. The structure can also serve as a basis for the design of novel, highly efficient inhibitors of HIV entry.

The difference of binding epitopes on human CD16 (FcγRIII) interacted with hIgG1 and monoclonal antibody B88-9

Effects of Anchor Structure and Glycosylation of Fc Gamma Receptor Iii on Ligand Binding Affinity

Molecular Recognition of Fc-Specific Ligands Binding Onto the Consensus Binding Site of Igg: Insights from Molecular Simulation

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Binding Activity Difference of Anti-Cd20 Scfv-Fc Fusion Protein Derived from Variable Domain Exchange.

Antigen Specificity Of Gamma Delta T Cells Depends Primarily On The Flanking Sequences Of Cdr3 Delta

Human IgG1 Cgamma1 Domain is Crucial for the Bioactivity of the Engineered Anti-Cd20 Antibodies.

Human IgG 1 C γ 1 Domain Is Crucial for the Bioactivity of the Engineered Anti-CD 20 Antibodies

Structural Insights into Immunoglobulin M

Hinge influences in murine IgG binding to Cryptococcus neoformans capsule

Design and assembly of anti-CD16 ScFv antibody with two different linker peptides.

Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1

Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purified human B cells

Interaction of human IgG chimeric antibodies with the human FcRI and FcRII receptors: Requirements for antibody-mediated host cell-target cell interaction

Influence of glycan modification on IgG1 biochemical and biophysical properties

Orientation of the Ig domains of CD8 alpha beta relative to MHC class I

Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Benchmarking glycoform-resolved affinity separation – mass spectrometry assays for studying FcγRIIIa binding

Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.